Bristol Myers Squibb Signs Licensing Deal with Avidity Biosciences for Multiple Cardiovascular Targets

By Shweta Gupta

Pharma Deals Review: Vol 2023 Issue 12 (Table of Contents)

Published: 13 Dec-2023

DOI: 10.3833/pdr.v2023.i12.2843     ISSN: 1756-7874

Section: Research & Development



In order to strengthen its cardiovascular portfolio, Bristol Myers Squibb (BMS) has entered into a development and commercialisation agreement with Avidity Biosciences to create RNA-based medicines for cardiovascular diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details